Covaxin shows 50% effectiveness against symptomatic COVID in real-world assessment: Lancet study

Two doses of Covaxin are 50 per cent effective against symptomatic COVID-19, according to the first real-world assessment of India's indigenous coronavirus vaccine published in The Lancet Infectious Diseases journal.

Two doses of Covaxin are 50 per cent effective against symptomatic COVID-19, according to the first real-world assessment of India's indigenous coronavirus vaccine published in The Lancet Infectious Diseases journal. November 24, 2021 at 08:53AM https://ift.tt/3CM3axG